Access Vascular

Executive Summary

Access Vascular is a private medical device company focused on reducing catheter-related complications through its proprietary hydrogel-based PICC and Midline devices. Founded in 2013 and headquartered in Billerica, Massachusetts, the company aims to address the significant clinical and economic burden of catheter-induced thrombosis and occlusion. By utilizing a hydrophilic material that mimics native tissue, Access Vascular's technology seeks to improve patient outcomes and reduce healthcare costs associated with catheter failure, replacement, and infection. While the company operates in a competitive vascular access market, its differentiated hydrogel platform offers potential advantages in biocompatibility and thrombus resistance. As a private entity with limited public information, Access Vascular's progress depends on regulatory clearances, clinical evidence generation, and commercial traction. The company's ability to secure FDA approvals or partnerships will be critical for growth.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Next-Generation Hydrogel Catheter70% success
• Q4 2026Publication of Clinical Study Results Demonstrating Reduced Thrombosis Rates60% success
• Q2 2026Strategic Partnership or Distribution Agreement with Major Hospital Network50% success